1Mezzano SA,Droguett MA,Burgos ME,et al.Over expression of chemokines,fibrogenie cytokines and myofibroblasts in human membranous nephropathy[J].Kidney Int,2000,57 (1):147-158.
2Epstein M.Aldosterone as a mediator of progressive renal disease:pathogenetic and clinical implications[J].Am J Kidney Dis,2001,37(4):677-688.
6Dworkin LD,Gong R,Tolbert E,et al.Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury[J].Kidney Int,2004,65 (2):409-419.
7Zeisberga M,Kalluria R.Experimental strategies to reverse chronic renal disease[J].Blood Purif,2004,22(5):440-445.
4Minino AM, Heron MP, Murphy SL, et al. Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System. Deaths: final data for 2004 [J]. Natl Vital Star Rep,2007,55(19) :1-119.
5Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults[J]. Hypertens Res,2007,30(10) :937-943.
6Lueove J,Vupputuri S,Heiss G,et al. Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study[J]. Am J Kidney Dis,2008,51(1) :21-28.
7Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) [J]. Kidney Int, 2005,67(6) : 2089-2100.
8Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease [J].J Am Soc Nephrol, 2006,17 (10) : 2937-2944.
9Garg AX,Kiberd BA, Clark WF, et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES Ⅲ[J]. Kidney Int, 2002,61(6):2165- 2175.
10Belto AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease..a global challenge [J].Kidney Int Suppl, 2005, (98) :S11-S17.
